Abstract: An integrative pharmacokinetic/pharmacodynamics (PK/PD) ESA-EpoR mathematical model calculates the binding behavior of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.

Abstract: An integrative pharmacokinetic/pharmacodynamics (PK/PD) ESA-EpoR mathematical model calculates the binding behavior of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.

Abstract: The present invention pertains to the diagnosis of a high risk of mortality or other adverse events in a patient suffering from anemia, for example anemia caused by chemotherapy, cancer or chronic inflammation such as chronic kidney disease (CKD). The invention provides means to diagnose a patient who receives Erythropoiesis Stimulating Agents (ESA) and suffer from an adverse event if the treatment with the ESA is continued. Based on the herein disclosed methods, the clinician will be able to diagnose the prevalence of a fatal event and adjust the treatment of the anemia in the patient accordingly.

Abstract: The present invention pertains to the use of an Integrative pharmacokinetic/pharmacodynamic (PK/PD) ESA-EpoR mathematical model for calculating the binding behaviour of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.

Abstract: The invention relates to a method for monitoring a measurement device, in particular a flow measurement device, and to a measurement device itself. In order in this case to reliably preclude measurement errors resulting from incorrect installation, the invention proposes that a characteristic variable is calculated from a time series s(t) of the measurement signal of a measurement device and is compared with previously recorded reference values, with this being used as the basis to automatically generate a message as to whether the measurement device has been installed correctly or incorrectly.

Abstract: A measuring instrument whose measuring principle is based on an oscillator, for example an eddy counter, and in which there is arranged a sensor for recording a measured signal (S(t)), which can be supplied to an evaluation unit (2), characterized in that, from the phase increments psi(tau,t), that is to say from the differences between the instantaneous values phi(t) of the phase signal derived from the measured signal S(t) in a phase extractor (18) and values phi(t-tau) time-delayed by a delayed time tau, a coupling indicator value (KI) is formed in such a way that the existence of phase coupling with a further oscillator can be detected on the latter by means of comparison with a coupling reference value (KR).

Abstract: The invention relates to a method for monitoring a measurement device, in particular a flow measurement device, and to a measurement device itself. In order in this case to reliably preclude measurement errors resulting from incorrect installation, the invention proposes that a characteristic variable is calculated from a time series s(t) of the measurement signal of a measurement device and is compared with previously recorded reference values, with this being used as the basis to automatically generate a message as to whether the measurement device has been installed correctly or incorrectly.

Abstract: A measuring instrument whose measuring principle is based on an oscillator, for example an eddy counter, and in which there is arranged a sensor for recording a measured signal (S(t)), which can be supplied to an evaluation unit (2), characterized in that, from the phase increments psi(tau,t), that is to say from the differences between the instantaneous values phi(t) of the phase signal derived from the measured signal S(t) in a phase extractor (18) and values phi(t-tau) time-delayed by a delayed time tau, a coupling indicator value (KI) is formed in such a way that the existence of phase coupling with a further oscillator can be detected on the latter by means of comparison with a coupling reference value (KR).